Home › Ovarian Epithelial Carcinoma › Indiana
Ovarian Epithelial Carcinoma clinical trials in Indiana
3 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in Indiana.
Cities in Indiana
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Parkview Research Center /ID# 274338, Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Fort Wayne
- Research Site, Indianapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Indiana University, Indianapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.